China unveiled new inclusions in its national reimbursement drug list, featuring novel therapies from Biogen, Pfizer, Eli Lilly and more. Partners Biocon and Viatris are …
With a recent pruritus approval in the books and several more potential launches coming in the next year and a half, Switzerland’s Vifor Pharma is …
On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign …
CStone will initiate a multi-center Phase I clinical trial to assess the safety, tolerability and preliminary anti-tumor activity of CS1003 in Chinese patients with advanced …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
